Listen: The plight of the VC, Gilead’s latest setback, & more M&A
Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to say someone overpaid?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how biotech’s downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.
Read Original Article: Listen: The plight of the VC, Gilead’s latest setback, & more M&A »
